Top

European Journal of Nutrition

Published in:

01-03-2022 | Alzheimer's Disease | Review

Dietary and supplemental long-chain omega-3 fatty acids as moderators of cognitive impairment and Alzheimer’s disease

Authors: Amy H. R. Wood, Helen F. Chappell, Michael A. Zulyniak

Published in: European Journal of Nutrition | Issue 2/2022

Abstract

Purpose

There is an ever-growing body of literature examining the relationship between dietary omega-3 polyunsaturated fatty acids (ω3 PUFAs) and cerebral structure and function throughout life. In light of this, the use of ω3 PUFAs, namely, long-chain (LC) ω3 PUFAs (i.e., eicosapentaenoic acid and docosahexaenoic acid), as a therapeutic strategy to mitigate cognitive impairment, and progression to Alzheimer’s disease is an attractive prospect. This review aims to summarise evidence reported by observational studies and clinical trials that investigated the role of LC ω3 PUFAs against cognition impairment and future risk of Alzheimer’s disease.

Methods

Studies were identified in PubMed and Scopus using the search terms “omega-3 fatty acids”, “Alzheimer’s disease” and “cognition”, along with common variants. Inclusion criteria included observational or randomised controlled trials (RCTs) with all participants aged ≥ 50 years that reported on the association between LC ω3 PUFAs and cognitive function or biological markers indicative of cognitive function linked to Alzheimer’s disease.

Results

Evidence from 33 studies suggests that dietary and supplemental LC ω3 PUFAs have a protective effect against cognitive impairment. Synaptic plasticity, neuronal membrane fluidity, neuroinflammation, and changes in expression of genes linked to cognitive decline have been identified as potential targets of LC ω3 PUFAs. The protective effects LC ω3 PUFAs on cognitive function and reduced risk of Alzheimer’s disease were supported by both observational studies and RCTs, with RCTs suggesting a more pronounced effect in individuals with early and mild cognitive impairment.

Conclusion

The findings of this review suggest that individuals consuming higher amounts of LC ω3 PUFAs are less likely to develop cognitive impairment and that, as a preventative strategy against Alzheimer’s disease, it is most effective when dietary LC ω3 PUFAs are consumed prior to or in the early stages of cognitive decline.

Available only for authorised users

Gale SA, Acar D, Daffner KR (2018) Dementia. Am J Med 131:1161–1169. https://doi.org/10.1016/j.amjmed.2018.01.022CrossRefPubMed

Patterson C (2018) World Alzheimer report 2018. Alzheimer’s Disease International, London

Alzheimer’s Association (2018) Alzheimer’s disease facts and figures. Alzheimer’s Assoc Rep 14:367–429. https://doi.org/10.1016/j.jalz.2018.02.001CrossRef

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):263–269. https://doi.org/10.1016/j.jalz.2011.03.005CrossRefPubMedPubMedCentral

Lam B, Masellis M, Freedman M, Stuss DT, Black SE (2013) Clinical, imaging, and pathological heterogeneity of the Alzheimer’s disease syndrome. Alz Res Ther 5:1. https://doi.org/10.1186/alzrt155CrossRef

Hill E, Goodwill AM, Gorelik A, Szoeke C (2019) Diet and biomarkers of Alzheimer’s disease: a systematic review and meta-analysis. Neurobiol Aging 76:45–52. https://doi.org/10.1016/j.neurobiolaging.2018.12.008CrossRefPubMed

Yusufov M, Weyandt LL, Piryatinsky I (2017) Alzheimer’s disease and diet: a systematic review. Int J Neurosci 127(2):161–175. https://doi.org/10.3109/00207454.2016.1155572CrossRefPubMed

Bartochowski Z, Conway J, Wallach Y, Chakkamparambil B, Alakkassery S, Grossberg GT (2020) Dietary interventions to prevent or delay Alzheimer’s disease: what the evidence shows. Curr Nutr Rep 9(3):210–225. https://doi.org/10.1007/s13668-020-00333-1CrossRefPubMed

van de Rest O, Berendsen AA, Haveman-Nies A, de Groot LC (2015) Dietary patterns, cognitive decline, and dementia: a systematic review. Adv Nutr 6(2):154–168. https://doi.org/10.3945/an.114.007617CrossRefPubMedPubMedCentral

10.

Talaei M, Koh WP, Yuan JM, van Dam RM (2019) DASH dietary pattern, mediation by mineral intakes, and the risk of coronary artery disease and stroke mortality. J Am Heart Assoc 8(5):e011054. https://doi.org/10.1161/jaha.118.011054CrossRefPubMedPubMedCentral

11.

Luchtman DW, Song C (2013) Cognitive enhancement by omega-3 fatty acids from child-hood to old age: findings from animal and clinical studies. Neuropharmacology 64:550–565. https://doi.org/10.1016/j.neuropharm.2012.07.019CrossRefPubMed

12.

Yehuda S, Rabinovitz S, Carasso RL, Mostofsky DI (2002) The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol Aging 23:843–853. https://doi.org/10.1016/S0197-4580(02)00074-XCrossRefPubMed

13.

Saini RK, Keum YS (2018) Omega-3 and omega-6 polyunsaturated fatty acids: Dietary sources, metabolism, and significance —A review. Life Sci 203:255–267. https://doi.org/10.1016/j.lfs.2018.04.049CrossRefPubMed

14.

Dyall SC, Michael-Titus AT (2008) Neurological benefits of Omega-3 fatty acids. Neuromol Med 10:219–235. https://doi.org/10.1007/s12017-008-8036-zCrossRef

15.

Brenna JT (2002) Efficiency of conversion of alpha-linolenic acid to long-chain n-3 fatty acids in man. Curr Opin Clin Nutr Metab Care 5:127–132. https://doi.org/10.1097/00075197-200203000-00002CrossRefPubMed

16.

Public Health England (2015) Composition of foods integrated dataset (CoFID). https://www.gov.uk/government/publications/composition-of-foods-integrated-dataset-cofid. Accessed 5 May 2020

17.

Givens DI, Gibbs RA (2008) Current intakes of EPA and DHA in European populations and the potential of animal-derived foods to increase them: symposium on ‘How can the n-3 content of the diet be improved?’. Proc Nutr Soc 67:273–280. https://doi.org/10.1017/s0029665108007167CrossRef

18.

Scientific Advisory Committee on Nutrition (2004) Advice on fish consumption: benefits and risks. TSO, London. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/338801/SACN_Advice_on_Fish_Consumption.pdf. Accessed 1 Nov 2020

19.

Simopoulos A (2002) The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 56:365–379. https://doi.org/10.1016/s0753-3322(02)00253-6CrossRefPubMed

20.

Simopoulos AP (2006) Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother 60:502–507. https://doi.org/10.1016/j.biopha.2006.07.080CrossRefPubMed

21.

Muskiet FAJ (2010) Pathophysiology and evolutionary aspects of dietary fats and long-chain polyunsaturated fatty acids across the life cycle. In: Montmayeur JP, le Coutre J (eds) Fat detection taste, texture and post ingestive effects. CRC Press/Taylor and Francis, Boca Raton

22.

Janssen CI, Kiliaan AJ (2014) Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neuronal development, aging, and neurodegeneration. Prog Lipid Res 53:1–17. https://doi.org/10.1016/j.plipres.2013.10.002CrossRefPubMed

23.

Park YH, Shin SJ, Kim HS, Hong SB, Kim S, Nam Y, Kim JJ, Lim K, Kim JS, Kim JI, Jeon SG, Moon M (2020) Omega-3 fatty acid-type Docosahexaenoic acid protects against Aβ-mediated mitochondrial deficits and pathomechanisms in Alzheimer’s disease-related animal model. Int J Mol Sci 21(11):3879. https://doi.org/10.3390/ijms21113879CrossRefPubMedCentral

24.

Giorgi PL, Biraghi M, Kantar A (1998) Effect of desmopressin on rat brain synaptosomal membranes: a pilot study. Curr Therap Res 59:172–178. https://doi.org/10.1016/S0011-393X(98)85013-3CrossRef

25.

Vignini A, Alia S, Pugnaloni S, Giulietti A, Bacchetti T, Mazzanti L, Luzzi S, Fiorini R (2019) Erythrocyte membrane fluidity in mild cognitive impairment and Alzheimer’s disease patients. Exp Gerontol 128:110754. https://doi.org/10.1016/j.exger.2019.110754CrossRefPubMed

26.

McGahon BM, Martin DSD, Horrobin DF, Lynch MA (1999) Age-related changes in synaptic function: analysis of the effect of dietary supplementation with ω-3 fatty acids. Neurosci 94:305–314. https://doi.org/10.1016/S0306-4522(99)00219-5CrossRef

27.

Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR, Weiner M, Shinto L, Aisen PS (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 304:1903–1911. https://doi.org/10.1001/jama.2010.1510CrossRefPubMedPubMedCentral

28.

Zhang YP, Miao R, Li Q, Wu T, Ma F (2017) Effects of DHA supplementation on hippocampal volume and cognitive function in older adults with mild cognitive impairment: a 12-month randomized, double-blind, placebo-controlled trial. J Alzheimers Dis 55:497–507. https://doi.org/10.3233/JAD-160439CrossRefPubMed

29.

Kitajka K, Sinclair AJ, Weisinger RS, Weisinger HS, Mathai M, Jayasooriya AP, Halver JE, Puskás LG (2004) Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. PNAS 101:10931–10936. https://doi.org/10.1073/pnas.0402342101CrossRefPubMedPubMedCentral

30.

Lane MA, Bailey SJ (2005) Role of retinoid signalling in the adult brain. Prog Neurobiol 75:275–293. https://doi.org/10.1016/j.pneurobio.2005.03.002CrossRefPubMed

31.

Schmitz G, Ecker J (2008) The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 47:147–155. https://doi.org/10.1016/j.plipres.2007.12.004CrossRefPubMed

32.

Bordoni A, Nunzio MD, Danesi F, Biagi PL (2006) Polyunsaturated fatty acids: from diet to binding to PPARs and other nuclear receptors. Genes Nutr 1:95–106. https://doi.org/10.1007/BF02829951CrossRefPubMedPubMedCentral

33.

Li X, Buxbaum JN (2011) Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer’s disease? Mol Neurodegeneration 6:79. https://doi.org/10.1186/1750-1326-6-79CrossRef

34.

Zhang M, Xv GH, Wang WX, Meng DJ, Ji Y (2017) Electroacupuncture improves cognitive deficits and activates PPAR-γ in a rat model of Alzheimer’s disease. Acupunct Med 35(1):44–51. https://doi.org/10.1136/acupmed-2015-010972CrossRefPubMed

35.

Hajjar T, Meng GY, Rajion MA, Vidyadaran S, Othman F, Farjam AS, Li TA, Ebrahimi M (2012) Omega 3 polyunsaturated fatty acid improves spatial learning and hippocampal peroxisome proliferator activated receptors (PPARα and PPARγ) gene expression in rats. BMC Neurosci 13:109. https://doi.org/10.1186/1471-2202-13-109CrossRefPubMedPubMedCentral

36.

Bhatti GK, Reddy AP, Reddy PH, Bhatti JS (2020) Lifestyle modifications and nutritional interventions in aging-associated cognitive decline and Alzheimer’s disease. Front Aging Neurosci 11:369. https://doi.org/10.3389/fnagi.2019.00369CrossRefPubMedPubMedCentral

37.

Calder PC (2006) n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83:1505S-1519S. https://doi.org/10.1093/ajcn/83.6.1505SCrossRefPubMed

38.

Zulyniak MA, Perreault M, Gerling C, Spriet LL, Mutch DM (2013) Fish oil supplementation alters circulating eicosanoid concentrations in young healthy men. Metabolism 62(8):1107–1113. https://doi.org/10.1016/j.metabol.2013.02.004CrossRefPubMed

39.

Biringer RG (2019) The role of eicosanoids in Alzheimer’s disease. Int J Environ Res Public Heath 16:2560. https://doi.org/10.3390/ijerph16142560CrossRef

40.

Herbst-Robinson KJ, Liu L, James M, Yao Y, Xie SX, Brunden KR (2015) Inflammatory eicosanoids increase amyloid precursor protein expression via activation of multiple neuronal receptors. Sci Rep 5:18286. https://doi.org/10.1038/srep18286CrossRefPubMedPubMedCentral

41.

Zulyniak MA, Roke K, Gerling C, Logan SL, Spriet LL, Mutch DM (2016) Fish oil regulates blood fatty acid composition and oxylipin levels in healthy humans: a comparison of young and older men. Mol Nutr Food Res 60(3):631–641. https://doi.org/10.1002/mnfr.201500830CrossRefPubMed

42.

Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST (2003) Differential effects of prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. PNAS 100:1751–1756. https://doi.org/10.1073/pnas.0334211100CrossRefPubMedPubMedCentral

43.

Bazan NG (2009) Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotection D1 signalling in photoreceptor cell survival and brain protection. Prostaglandins Leukot Essent Fatty Acids 81:205–211. https://doi.org/10.1016/j.plefa.2009.05.024CrossRefPubMedPubMedCentral

44.

Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 115:2774–2783. https://doi.org/10.1172/JCI25420CrossRefPubMedPubMedCentral

45.

Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM (1997) Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 42:776–782. https://doi.org/10.1002/ana.410420514CrossRefPubMed

46.

Devore EE, Grodstein F, van Rooij FJA, Hofman A, Rosner B, Stampfer MJ, Witteman JCM, Breteler MMB (2009) Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am J Clin Nutr 90:170–176. https://doi.org/10.3945/ajcn.2008.27037CrossRefPubMedPubMedCentral

47.

Huang TL, Zandi PP, Tucker KL, Fitzpatrick AL, Kuller LH, Fried LP, Burke GL, Carlson MC (2005) Benefits of fatty fish on dementia risk are stronger for those without APOE ɛ4. Neurology 65:1409–1414. https://doi.org/10.1212/01.wnl.0000183148.34197.2eCrossRefPubMed

48.

Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, Aggarwal N, Schneider J (2003) Consumption of fish and n-3 fatty acids and risk of incident alzheimer disease. Arch Neurol 60:940–946. https://doi.org/10.1001/archneur.60.7.940CrossRefPubMed

49.

Nurk E, Drevon CA, Refsum H, Solvoll K, Vollset SE, Nygård O, Nygaard HA, Engedal K, Tell GS, Smith AD (2007) Cognitive performance among the elderly and dietary fish intake: the Hordaland Health Study. Am J Clin Nutr 86:1470–1478. https://doi.org/10.1093/ajcn/86.5.1470CrossRefPubMed

50.

Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, Wilson PWF, Wolf PA (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the framingham heart study. Arch Neurol 63:1545–1550. https://doi.org/10.1001/archneur.63.11.1545CrossRefPubMed

51.

Lawson LD, Hughes BG (1988) Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat meal. Biochem Biophys Res Commun 156:960–963. https://doi.org/10.1016/s0006-291x(88)80937-9CrossRefPubMed

52.

Szlinder-Richert J, Usydus Z, Malesa-Ciećwierz M, Polak-Juszczak L, Ruczyńska W (2011) Marine and farmed fish on the Polish market: comparison of the nutritive value and human exposure to PCDD/Fs and other contaminants. Chemosphere 85(11):1725–1733. https://doi.org/10.1016/j.chemosphere.2011.09.019CrossRefPubMed

53.

Li G, Sinclair AJ, Li D (2011) Comparison of lipid content and fatty acid composition in the edible meat of wild and cultured freshwater and marine fish and shrimps from china. J Agric Food Chem 59(5):1871–1881. https://doi.org/10.1021/jf104154qCrossRefPubMed

54.

Morris MC, Tangney CC, Wang Y, Sacks FM, Bennett DA, Aggarwal NT (2015) MIND diet associated with reduced incidence of Alzheimer’s disease. Alzheimers Dement 11:1007–1014. https://doi.org/10.1016/j.jalz.2014.11.009CrossRefPubMedPubMedCentral

55.

Bell KE, Fang H, Snijders T, Allison DJ, Zulyniak MA, Chabowski A, Parise G, Phillips SM, Heisz JJ (2019) A multi-ingredient nutritional supplement in combination with resistance exercise and high-intensity interval training improves cognitive function and increases n-3 index in healthy older men: a randomized controlled trial. Front Aging Neurosci 11:107. https://doi.org/10.3389/fnagi.2019.00107CrossRefPubMedPubMedCentral

56.

van de Rest O, Wang Y, Barnes LL, Tangney C, Bennett DA, Morris MC (2016) APOE ε4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline. Neurology 86:2063–2070. https://doi.org/10.1212/WNL.0000000000002719CrossRefPubMedPubMedCentral

57.

Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63:1402–1408. https://doi.org/10.1001/archneur.63.10.1402CrossRefPubMed

58.

Eriksdotter M, Vedin I, Falahati F, Freund-Levi Y, Hjorth E, Faxén-Irving G, Wahlund LO, Schultzberg M, Basun H, Cederholm T, Palmblad J (2015) Plasma fatty acid profiles in relation to cognition and gender in alzheimer’s disease patients during oral Omega-3 fatty acid supplementation: the omegad study. J Alzheimers Dis 48:805–812. https://doi.org/10.3233/JAD-150102CrossRefPubMed

59.

Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY (2008) The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 32:1538–1544. https://doi.org/10.1016/j.pnpbp.2008.05.015CrossRefPubMed

60.

Zhang YP, Lou Y, Hu J, Miao R, Ma F (2018) DHA supplementation improve cognitive function via enhancing Aβ-mediated autophagy in Chinese elderly with mild cognitive impairment: a randomised placebo-controlled trial. J Neurol Neurosurg Psychiatry 89:382–388. https://doi.org/10.1136/jnnp-2017-316176CrossRefPubMed

61.

Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, Salem N, Stedman M (2010) Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 6:456–464. https://doi.org/10.1016/j.jalz.2010.01.013CrossRefPubMed

62.

Lee LK, Shahar S, Chin AV, Yusoff NAM (2012) Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology 225:605–612. https://doi.org/10.1007/s00213-012-2848-0CrossRefPubMed

63.

Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y, Sakakibara M, Yoshimoto T, Guo J, Yamashima T (2006) Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 56:159–164. https://doi.org/10.1016/j.neures.2006.06.010CrossRefPubMed

64.

Phillips MA, Childs CE, Calder PC, Rogers PJ (2015) No effect of omega-3 fatty acid supplementation on cognition and mood in individuals with cognitive impairment and probable Alzheimer’s Disease: a randomised controlled trial. Int J Mol Sci 16:24600–24613. https://doi.org/10.3390/ijms161024600CrossRefPubMedPubMedCentral

65.

Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, Bories L, Cufi MN, Dantoine T, Dartigues JF et al (2017) Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol 16:377–389. https://doi.org/10.1016/S1474-4422(17)30040-6CrossRefPubMed

66.

Tabue-Teguo M, Barreto de Souza P, Cantet C, Andrieu S, Simo N, Fougère B, Dartigues JF, Vellas B (2018) Effect of multidomain intervention, omega-3 polyunsaturated fatty acids supplementation or their combination on cognitive function in non-demented older adults according to frail status; results from the mapt study. J Nutr Health Aging 22:923–927. https://doi.org/10.1007/s12603-018-1024-6CrossRefPubMed

67.

Geleijnse JM, Giltay EJ, Kromhout D (2012) Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients. Alzheimers Dement 8:278–287. https://doi.org/10.1016/j.jalz.2011.06.002CrossRefPubMed

68.

Chew EY, Clemons TE, Agrón E, Launer LJ, Grodstein F, Bernstein PS (2015) Effect of omega-3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA 314:791–801. https://doi.org/10.1001/jama.2015.9677CrossRefPubMedPubMedCentral

69.

Külzow N, Witte AV, Kerti L, Grittner U, Schuchardt JP, Hahn A, Flöel A (2016) Impact of omega-3 fatty acid supplementation on memory functions in healthy older adults. J Alzheimers Dis 51:713–725. https://doi.org/10.3233/JAD-150886CrossRefPubMed

70.

Hooper C, de Souto BP, Coley N, Cantet C, Cesari M, Andrieu S, Vellas B (2017) Cognitive changes with omega-3 polyunsaturated fatty acids in non-demented older adults with low omega-3 index. J Nutr Health Aging 21:988–993. https://doi.org/10.1007/s12603-017-0957-5CrossRefPubMed

71.

Mahmoudi MJ, Hedayat M, Sharifi F, Mirarefin M, Nazari N, Mehrdad N, Ghaderpanahi M, Tajalizadekhoob Y, Badamchizade Z, Larijani B et al (2014) Effect of low dose ω-3 poly unsaturated fatty acids on cognitive status among older people: a double-blind randomized placebo-controlled study. J Diabetes Metab Disord 13:34. https://doi.org/10.1186/2251-6581-13-34CrossRefPubMedPubMedCentral

72.

Scheltens P, Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Wurtman RJ, Wilkinson D, Twisk JWR, Kurz A (2010) Efficacy of a medical food in mild Alzheimer’s disease: a randomized, controlled trial. Alzheimers Dement 6:1–10. https://doi.org/10.1016/j.jalz.2009.10.003CrossRefPubMed

73.

Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, Hartmann T (2017) 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol 16:965–975. https://doi.org/10.1016/S1474-4422(17)30332-0CrossRefPubMedPubMedCentral

74.

Hamel, R, Köhler S, Sistermans N, Koene T, Pijnenburg Y, van der Flier W, Scheltens P, Aalten P, Verhey F, Visser PJ, Ramakers I (2015) The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study. Psychol Med 45:1509–1519. https://doi.org/10.1017/s0033291714002645

75.

Jernerén F, Elshorbagy AK, Oulhaj A, Smith SM, Refsum H, Smith AD (2015) Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B Vitamin status in a randomized controlled trial. Am J Clin Nutr 102:215–221. https://doi.org/10.3945/ajcn.114.103283CrossRefPubMed

76.

Malouf M, Grimley EJ (2008) Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev 4:CD004514. https://doi.org/10.1002/14651858.cd004514CrossRef

77.

Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, Waichunas D, Bumgarner L, Bourdette D, Silbert L, Jeffrey K (2014) A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease. J Alzheimers Dis 38:111–120. https://doi.org/10.3233/JAD-130722CrossRefPubMed

78.

Park S, Karunakaran U, Jeoung NH, Jeon JH, Lee IK (2014) Physiological effect and therapeutic application of alpha lipoic acid. Curr Med Chem 21:3636–3645. https://doi.org/10.2174/0929867321666140706141806CrossRefPubMed

79.

Freund-Levi Y, Hjorth E, Lindberg C, Cederholm T, Faxen-Irving G, Vedin I, Palmblad J, Wahlund LO, Schultzberg M, Basun H, Eriksdotter-Jönhagen M (2009) Effects of Omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer’s disease: the OmegAD study. Dement Geriatr Cogn Disord 27:481–490. https://doi.org/10.1159/000218081CrossRefPubMed

80.

Freund-Levi Y, Vedin I, Hjorth E, Basun H, Faxén-Irving G, Schultzberg M, Eriksdotter M, Palmblad J, Vessby B, Wahlund LO, Cederholm T, Basu S (2014) Effects of supplementation with Omega-3 fatty acids on oxidative stress and inflammation in patients with Alzheimer’s disease: the OmegAD study. J Alzheimers Dis 42:823–831. https://doi.org/10.3233/JAD-132042CrossRefPubMed

81.

Schwarz C, Wirth M, Gerischer L, Grittner U, Witte AV, Köbe T, Flöel A (2017) Effects of omega-3 fatty acids on resting cerebral perfusion in patients with mild cognitive impairment: a randomized controlled trial. J Prev Alzheimers Dis 5:26–30. https://doi.org/10.14283/jpad.2017.23

82.

Fiala M, Halder RC, Sagong B, Ross O, Sayre J, Porter V, Bredesen DE (2015) ω-3 Supplementation increases amyloid-β phagocytosis and resolvin D1 in patients with minor cognitive impairment. FASEB J 29:2681–2689. https://doi.org/10.1096/fj.14-264218CrossRefPubMed

83.

Faxén-Irving G, Freund-Levi Y, Eriksdotter-Jönhagen M, Basun H, Hjorth E, Palmblad J, Vedin I, Cederholm T, Wahlund LO (2013) Effects on Transthyretin in plasma and cerebrospinal fluid by DHA-Rich n-3 fatty acid supplementation in patients with Alzheimer’s disease: the OmegAD study. J Alzheimers Dis 36:1–6. https://doi.org/10.3233/JAD-121828CrossRefPubMed

84.

Fernández-Sanz P, Ruiz-Gabarre D, García-Escudero V (2019) Modulating effect of diet on Alzheimer’s disease. Diseases 7:12. https://doi.org/10.3390/diseases7010012CrossRefPubMedCentral

85.

Lacalle-Aurioles M, Mateos-Pérez JM, Guzmán-De-Villoria JA, Olazarán J, Cruz-Orduña I, Alemán-Gómez Y, Martino ME, Desco M (2014) Cerebral blood flow is an earlier indicator of perfusion abnormalities than cerebral blood volume in Alzheimer’s disease. J Cereb Blood Flow Metab 34:654–659. https://doi.org/10.1038/jcbfm.2013.241CrossRefPubMedPubMedCentral

86.

Marteinsdottir I, Horrobin DF, Stenfors C, Theodorsson E, Mathé AA (1998) Changes in dietary fatty acids alter phospholipid fatty acid composition in selected regions of rat brain. Prog Neuropsychopharmacol Biol Psychiatry 22:1007–1021. https://doi.org/10.1016/S0278-5846(98)00052-9CrossRefPubMed

Title: Dietary and supplemental long-chain omega-3 fatty acids as moderators of cognitive impairment and Alzheimer’s disease
Authors: Amy H. R. Wood
Helen F. Chappell
Michael A. Zulyniak
Publication date: 01-03-2022
Publisher: Springer Berlin Heidelberg
Keywords: Alzheimer's Disease
Alzheimer's Disease
Mild Neurocognitive Disorder
Published in: European Journal of Nutrition / Issue 2/2022
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-021-02655-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2022

Effectiveness of a polyphenolic extract (Lippia citriodora and Hibiscus sabdariffa) on appetite regulation in overweight and obese grade I population: an 8-week randomized, double-blind, cross-over, placebo-controlled trial

Individual participant data (IPD)-level meta-analysis of randomised controlled trials to estimate the vitamin D dietary requirements in dark-skinned individuals resident at high latitude

Vitamin D status is not associated with clinical severity of COVID-19 in pregnant women

Pulse consumption improves indices of glycemic control in adults with and without type 2 diabetes: a systematic review and meta-analysis of acute and long-term randomized controlled trials

Rice (Oryza sativa L.) bran preserves cardiac function by modulating pro-inflammatory cytokines and redox state in the myocardium from obese rats

Relationship of maternal obesity and vitamin D concentrations with fetal growth in early pregnancy

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage